Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.

Li H, Zuo J, Tang W. · 2018

Read Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases. by Li H, Zuo J, Tang W. (2018) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6199465.txt.

Introduction

Li and co-authors wrote a review in Frontiers in Pharmacology on PDE4 inhibitors for inflammatory diseases. PDE4 is an enzyme found mainly in immune, airway, and brain cells. It shapes inflammation and the integrity of epithelial surfaces. Blocking it raises cAMP, a messenger that retunes many genes and proteins.

Three blockers have reached approval so far. Roflumilast treats inflammatory airway disease, apremilast treats psoriatic arthritis, and crisaborole treats atopic dermatitis. Trials in other conditions, including Behçet's syndrome, are also reviewed. Strong effects often come with adverse effects, which limit dosing. The review weighs that trade-off across the drug class and its many candidate compounds.

Catalog record

CREATORLi H, Zuo J, Tang W.
YEAR2018
COLLECTIONPAPERS
FORMATTXT
FILE SIZE98 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6199465

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases By Heng Li, Jianping Zuo, Wei Tang Published in: Frontiers in Pharmacology DOI: 10.3389/fphar.2018.01048 ABSTRACT Phosphodiesterase-4 (PDE4), mainly present in immune cells, epithelial cells, and brain cells, manifests as an intracellular non-receptor enzyme that modulates inflammation and epithelial integrity. Inhibition of PDE4 is predicted to have diverse effects via the elevation of the level of cyclic adenosine monophosphate (cAMP) and the subsequent regulation of a wide array of genes and proteins. It has been identified that PDE4 is a promising therapeutic target for the treatment of diverse pulmonary, dermatological, and severe neurological diseases. Over the past decades, numerous PDE4 inhibitors have been designed and synthesized, among which roflumilast, apremilast, and crisaborole were approved for the treatment of inflammatory airway diseases, psoriatic arthritis, and atopic dermatitis, respectively. It is regrettable that the dramatic efficacies of a drug are often accompanied by adverse effects, such as nausea, emesis, and gastrointestinal reactions. However, substantial advances have been made to mitigate the adverse effects and obtain better benefit-to-risk ratio. This review highlights the dialectical role of PDE4 in drug discovery and the disquisitive details of certain PDE4 inhibitors to provide an overview of the topics that still need to be addressed in the future. INTRODUCTION Inflammation underlies the pathogenesis of various human diseases, which includes infection, immune-mediated disorders, metabolic disturbance, neurodegeneration, and cancer. Inflammatory diseases affect a certain population worldwide and possess extremely complicated pathogenic mechanisms (Kazatchkine and Kaveri, 2001). To date, numerous therapeutic strategies have emerged in the treatment of inflammatory diseases (Tabas and Glass, 2013; Siebert et al., 2015). Though the non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids have made tremendous contributions for inflammation intervention, the serious long-term adverse effects and the multiple manifestations of diseases drive some patients away from these therapeutic options (Hart and Huskisson, 1984). Hence, there remains a great need for the discovery of novel therapeutic drugs for controlling inflammation (Uguccioni et al., 2017). Cyclic guanosine monophosphate (cGMP) and cyclic adenosine monophosphate (cAMP) function as the fundamental second messengers in the regulation of multiple cellular metabolisms. Phosphodiesterases (PDEs), consisting of 11 families (PDE1–PDE11), are available for the degradation of cyclic nucleotides (Kumar et al., 2013). Distributions of PDE subfamilies are diverse in different cells and tissues, which may provide a substantial support for their pharmacological research in the field of inflammation, cognition, lipogenesis, proliferation, apoptosis, and differentiation. The cAMP-specific PDE4 is highly expressed in the brain, cardiovascular tissues, smooth muscles, keratinocytes, and immunocytes (including T cells, monocytes, macrophages, neutrophils, dendritic cells, eosinophils) (Chiricozzi et al., 2016). The inhibition of PDE4 can elevate the intracellular level of cAMP and subsequently modulate the inflammatory responses and maintain the immune balance (Maurice et al., 2014). Targeting PDE4 has been verified as an effective therapeutic strategy for inflammatory conditions, including asthma, chronic obstructive pulmonary disease (COPD), psoriasis, atopic dermatitis (AD), inflammatory bowel diseases (IBD), rheumatic arthritis (RA), lupus, and neuroinflammation (as shown in Figure 1). Through great efforts, roflumilast, apremilast, and crisaborole were approved in succession for the treatment of inflammatory airway or skin diseases. Moreover, a series of novel PDE4 inhibitors have also been developed for the regulation of inflammation, and they showed satisfactory therapeutic efficacies. This review summarizes the chemical skeleton, pharmacological and clinical details of licensed PDE4 inhibitors in the process. Nausea, emesis, gastrointestinal effects, and other adverse effects have largely impeded the clinical application, which is attributed to PDE4 inhibition in the unexpected tissues. Hence, more efforts and emphasis are required to balance efficacy with minimizing adverse effects in the long and bumpy road to the development of more innovative drugs. [Figure: Pathological manifestations and PDE4 inhibitors in inflammatory diseases.] MODE OF ACTION: PDE4 INHIBITION IN THE REGULATION OF INFLAMMATION Phosphodiesterase-4 was found to be a dramatic downstream component of the β-adrenoceptor and N-methyl-D-aspartic acid receptor (NMDAR) mediated signaling pathway and also related to 5-hydroxytryptamine (5-HT) receptor (O'Donnell and Zhang, 2004). Receptors for activated C kinase 1 (RACK1) and A-kinase-anchoring proteins (AKAPs) and proteins that contain SH3 domains act as the interacting proteins that affect the intracellular localization and function of PDE4 (Maurice et al., 2014). Delicate combinations of cyclic nucleotide modulators, including protein kinase A (PKA), cyclic nucleotide-gated ion channels, and exchange factors directly activated by cAMP (Epac) with PDE4 contribute to the formation of cAMP signalosomes via protein-protein interactions, which showed multiple effects on cell proliferation, differentiation, and immune responses (Motte et al., 2017). Increasing evidence demonstrated that patients who suffered from inflammatory diseases showed higher expression of PDE4 than the healthy individuals (Schafer et al., 2016). There are four subtypes of PDE4, namely PDE4A–PDE4D, which are highly specific for cAMP degradation but not for cGMP. Inhibition of PDE4 results in the accumulation of intracellular cAMP and subsequently activates PKA, cyclic nucleotide-gated ion channels, and Epac1/2. These are involved in the regulation of pro-inflammatory and anti-inflammatory cytokines synthesis, activation of T cells, neutrophil degranulation, performance of antigen-presentation, and epithelial integrity via initiation of multiple downstream elements (as shown in Figure 2A). Release of catalytic subunit from regulatory subunit upon PKA activation could subsequently increase the phosphorylation of cAMP-responsive element binding protein (CREB), activating transcription factor 1 (ATF-1) and cAMP responsive element modulator (CREM) and recruit the CREB binding protein (CBP) or the homologous protein p300, leading to the reduction of inflammatory cytokines and the increase of anti-inflammatory cytokines (Schafer, 2012). A previous study demonstrated that the transcriptional activity of classic nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) can be stimulated upon the phosphorylation of p65 on Ser276 by PKA (Christian et al., 2016). The CBP/p300 is closely associated with NF-κB p65, and PKA activation could regulate the transcriptional activity of NF-κB through the modulation of its interaction with CBP/p300 without IκBα degradation or NF-κB DNA binding activity, which results in the downregulation of inflammatory responses (Zhong et al., 1998; Schafer, 2012). Additionally, PKA activation could interfere with B-cell lymphoma 6 protein (Bcl-6)-mediated synthesis of pro-inflammatory cytokines and proliferation of immune cells (Page, 2014; Hernández-Flórez and Valor, 2016). Activation of Epac1/2 in the wake of cAMP elevation serves as a promising alternative mechanism to target inflammation and proliferation (Lehrke et al., 2015). Compartmentalization of intracellular cAMP in space and time contributes to the Epac signalosome of transcription factors, small GTPases (Rap1), which do well in the optimization of the treatment of inflammatory airway diseases, renal failure, vasculature disturbance, and neuroinflammation (Schmidt et al., 2013). [Figure: Mode of PDE4 inhibition in the regulation of inflammatory responses. (A) PDE4 regulates the production of pro-inflammatory and anti-inflammatory cytokines and cell proliferation via the degradation of cAMP. PDE4 inhibition leads to the accumulation of intracellular cAMP, which can activate protein kinase A (PKA) and the exchange protein 1/2 activated by cAMP (Epac1/2). PKA activation results in the phosphorylation of cAMP-responsive element binding protein (CREB) and activating transcription factor 1 (ATF-1), leading to the increase in anti-inflammatory cytokines. The transcriptional activity of NF-κB can be regulated by PKA activation through the modulation of its interaction with CREB binding protein (CBP) or p300; meanwhile, PKA activation can interfere with the synthesis of B-cell lymphoma 6 protein (Bcl-6)-mediated pro-inflammatory cytokines and the proliferation of immune cells. Compartmentalization of intracellular cAMP contributes to the Epac signalosome of

Read the complete text